First mechanism based septic shock therapy! Nangibotide, a 12 peptide TREM-1 inhibitor, started the global phase IIB research!

November 28, 2019 / BIOON / -- inotrem S.A is a biotechnology company specializing in immunotherapy of acute and chronic inflammatory syndrome Recently, the company announced that it has launched the phase IIb asonish trial to evaluate the efficacy of nangbotide (lr12) in the treatment of septic shock, and incorporated the first patient into the group Septic shock is the final complication of sepsis In developed countries, the incidence of septic shock continues to rise and the mortality rate is still very high (35%) In addition to antibiotics and symptomatic treatment, there is no special drug approved for this indication Nangibotide has the potential to become the first mechanism based therapeutic drug for septic shock It is a TREM-1 inhibitor, which has the potential to restore appropriate inflammatory response, vascular function and improve the survival rate after septic shock In September this year, the U.S FDA granted nangibotide the fast track qualification (FTD) for the treatment of septic shock In 2017, the European Drug Administration (EMA) awarded the nangbotide priority drug qualification (prime) This global multicenter phase IIB study was launched to prove the efficacy of nangbotide and provide medical evidence for the clinical activity of septic shock patients In addition, the study will also validate an individualized medical approach, using soluble TREM-1 as a potential concomitant diagnostic test, to identify patients who are more likely to benefit from nangibotide treatment The study will be carried out in five European countries and 48 clinical sites in the United States, and a total of 450 patients will be enrolled Jean Jacques garaud, CEO and co-founder of inotrem, said: "the results of the astonish trial will be used to support the initiation of the phase III trial, and we hope that the trial can provide important insights into the clinical activity of nangibotide and the individualized medication methods in septic shock." Lr12 peptide can capture the ligand of TREM-1 and inhibit the participation of TREM-1, so as to regulate the inflammatory amplification loop (DOI: 10.1093 / CVR / cvy018) The innate immune system constitutes the first line of defense against invasive microbial pathogens TREM-1 is an immune receptor expressed on innate immune cells TREM-1 regulates inflammation and leads to a strong immune response Unlike most inhibitors, trem-1-based inhibitors have unique therapeutic ability: the use of immunomodulatory ability can control the cause of adverse effects observed by patients, but not completely eliminate the inflammatory response, which is still necessary, such as bacterial clearance Lr12 monomer structure (picture source: doi: 10.1002 / BMC 3877) inotrem company found that the TREM-1 pathway is the key factor leading to the imbalance of inflammatory response With this as the core goal, it developed an innovative individualized medical method based on the inhibition of TREM-1, which is used for the indication characterized by acute or chronic inflammatory syndrome Nangibotide is the preparation of active ingredient lr12, which is a chemically synthesized peptide with 12 amino acids in length Lr12 is a special TREM-1 inhibitor, which acts as a decoy receptor and interferes with the binding of TREM-1 to its ligand In the preclinical septic shock model, nangibotide can restore the appropriate inflammatory response, vascular function, and improve the survival rate after septic shock Source of original text: inotrem announcements enrollment of first patient in its phase IIb asonish trial for nangbotide in the treatment of selective shock